Streptococcal superantigens and the return of scarlet fever.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
entrez:
30
12
2021
pubmed:
31
12
2021
medline:
19
2
2022
Statut:
epublish
Résumé
Streptococcus pyogenes (group A Streptococcus) is a globally disseminated and human-adapted bacterial pathogen that causes a wide range of infections, including scarlet fever. Scarlet fever is a toxin-mediated disease characterized by the formation of an erythematous, sandpaper-like rash that typically occurs in children aged 5 to 15. This infectious disease is caused by toxins called superantigens, a family of highly potent immunomodulators. Although scarlet fever had largely declined in both prevalence and severity since the late 19th century, outbreaks have now reemerged in multiple geographical regions over the past decade. Here, we review recent findings that address the role of superantigens in promoting a fitness advantage for S. pyogenes within human populations and discuss how superantigens may be suitable targets for vaccination strategies.
Identifiants
pubmed: 34969060
doi: 10.1371/journal.ppat.1010097
pii: PPATHOGENS-D-21-01939
pmc: PMC8717983
doi:
Substances chimiques
Antigens, Bacterial
0
Superantigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010097Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect. 2019 May;78(5):358-363
pubmed: 30796950
Infect Immun. 2000 Sep;68(9):5011-7
pubmed: 10948118
Nat Genet. 2015 Jan;47(1):84-7
pubmed: 25401300
J Immunol. 2000 Aug 15;165(4):2306-12
pubmed: 10925320
Emerg Infect Dis. 2008 Oct;14(10):1511-7
pubmed: 18826812
Clin Exp Immunol. 2019 Jul;197(1):83-94
pubmed: 30815853
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10226-10231
pubmed: 28794279
BMC Genomics. 2017 Mar 10;18(1):224
pubmed: 28283023
Emerg Microbes Infect. 2012 Jul;1(7):e2
pubmed: 26038416
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728285
Vaccine. 2016 Jun 3;34(26):2953-2958
pubmed: 27032515
Sci Rep. 2015 Nov 02;5:15877
pubmed: 26522788
Sci Adv. 2019 Sep 04;5(9):eaax3013
pubmed: 31517054
Nat Genet. 2019 Jun;51(6):1035-1043
pubmed: 31133745
mBio. 2019 Apr 30;10(2):
pubmed: 31040243
Infect Immun. 1979 Nov;26(2):467-72
pubmed: 161910
Lancet Infect Dis. 2019 Nov;19(11):1209-1218
pubmed: 31519541
Annu Rev Microbiol. 2001;55:77-104
pubmed: 11544350
J Infect Dis. 2001 Jul 15;184(2):166-73
pubmed: 11424013
Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25923-25931
pubmed: 31772015
Trends Mol Med. 2014 Jan;20(1):48-62
pubmed: 24210845
J Infect Dis. 2012 Aug 1;206(3):341-51
pubmed: 22615319
Pediatr Infect Dis J. 2014 Mar;33(3):306-10
pubmed: 24168973
PLoS Pathog. 2014 May 29;10(5):e1004155
pubmed: 24875883
Clin Infect Dis. 1992 Jan;14(1):298-307
pubmed: 1571445
Eur J Epidemiol. 2000;16(7):619-26
pubmed: 11078118
Nat Commun. 2020 Oct 6;11(1):5018
pubmed: 33024089
Lancet Infect Dis. 2018 Aug;18(8):903-912
pubmed: 29858148
EBioMedicine. 2018 Feb;28:128-135
pubmed: 29342444
Lancet Infect Dis. 2018 Feb;18(2):128-129
pubmed: 29191627
Arch Dis Child. 1945 Mar;20(101):2-21
pubmed: 21032289